Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257648 | 1.00 | ADORA3 (0.39) | ADORA3ADORA2AADORA1CYP1A2HTR1A | |
| SCHEMBL13213500 | 1.00 | ADORA3 (0.39) | ADORA3ADORA2AADORA1CYP1A2HTR1A | |
| SCHEMBL13329959 | 0.89 | SLC29A1 (0.45) | ADORA3ADORA2AADORA1SLC29A1 | |
| SCHEMBL13360827 | 0.89 | SLC29A1 (0.45) | ADORA3ADORA2AADORA1SLC29A1 | |
| SCHEMBL13213648 | 0.89 | KDM4E (0.47) | KDM4E | |
| SCHEMBL13930526 | 0.89 | KDM4E (0.47) | KDM4E | |
| SCHEMBL13375771 | 0.83 | ADORA1 (0.40) | ADORA3ADORA2AADORA1CYP1A2LMNA | |
| SCHEMBL13930528 | 0.83 | POLB (0.50) | KDM4E | |
| SCHEMBL13213524 | 0.83 | POLB (0.50) | KDM4E | |
| SCHEMBL13930534 | 0.81 | ADORA1 (0.39) | ADORA3ADORA2AADORA1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288516-B2 | Functional molecule, functional molecule synthesizing amidite and target substance analysis method | FUJITSU LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | FUJITSU LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | TACR1, TACR2, ATIC | ADORA3 28/4885ADORA2A 39/4885ADORA1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.